EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T-cells

Abudureyimujiang Aili, Yuqing Wang, Ying Shang, Lijiao Zhang, Huan Liu, Zemin Li, Lixiang Xue, Yahong Chen, Yongchang Sun, Xu Zhang, Rong Jin, Chun Chang

European Respiratory Journal · 2024

DOI: 10.1183/13993003.01752-2023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Abudureyimujiang Aili und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Asthma, T-Lymphocytes, Regulatory, Biomarkers, Cell Differentiation. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The diagnosis, severity assessment, and development of therapeutic strategies for asthma are crucial aspects of disease management. Since biomarkers are reliable tools in disease management, we aimed to identify and explore asthma-associated biomarkers and investigate their mechanisms.

Methods

Lipidomics was used to profile serum glycerophospholipids in asthmatic patients and controls. The absolute concentration of lysophosphatidylglycerol (LPG) 18:0 was quantified in various asthma subtypes. Mouse asthma models were used to confirm its potential as a biomarker and investigate its mechanisms in vivo. The effects of LPG 18:0 on CD4 + T-cell differentiation, proliferation and apoptosis were assessed in vitro by flow cytometry, while mitochondrial dysfunction was evaluated through mitochondrial membrane potential, reactive oxygen species and ATP production measurements. The intracellular mechanism of LPG 18:0 in regulatory T-cells (Tregs) was investigated using small-molecule inhibitors.

Results

The serum glycerophospholipid profile varied between asthmatic patients and control group, with LPG 18:0 levels being notably higher in asthmatic patients, correlating with asthma severity and control level. In vivo and in vitro studies revealed that LPG 18:0 impaired naïve CD4 + T-cell differentiation into Tregs and compromised their suppressive function. Further investigation demonstrated that LPG 18:0 treatment reduced the FOXP3 protein level via SIRT1-mediated deacetylation during Treg differentiation.

Conclusions

This study identifies that serum levels of LPG 18:0 are generally elevated in asthmatics and serve as a biomarker for asthma. LPG 18:0 impairs Treg function via the NAD + /SIRT1/FOXP3 pathway. Our research reveals the potential of LPG 18:0 as a biomarker for asthma, elucidating its role in asthma diagnosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaT-Lymphocytes, RegulatoryBiomarkersCell DifferentiationHumansAnimalsMiceMaleFemaleAdultCase-Control StudiesMiddle AgedLysophospholipidsDisease Models, AnimalLipidomicsMice, Inbred BALB CCell ProliferationApoptosisReactive Oxygen Species

Substanzen

BiomarkersLysophospholipidsReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
  • Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
  • Abudureyimujiang Aili, Yuqing Wang and Ying Shang contributed equally to this work and should be considered co-first authors.
  • Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
  • Research Center for Chronic Airway Diseases, Peking University Health Science Center, Beijing, China.
  • Tianjin Key Laboratory of Metabolic Diseases, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Center for Cardiovascular Diseases, Research Center of Basic Medical Sciences…

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Aili, A., Wang, Y., Shang, Y., Zhang, L., Liu, H., Li, Z., Xue, L., Chen, Y., Sun, Y., Zhang, X., Jin, R., & Chang, C. (2024). LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T-cells. European Respiratory Journal. https://doi.org/10.1183/13993003.01752-2023

Vancouver

Aili A, Wang Y, Shang Y, Zhang L, Liu H, Li Z, et al. LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T-cells. European Respiratory Journal. 2024. doi:10.1183/13993003.01752-2023

BibTeX
@article{Aili2024,
  author = {Aili, Abudureyimujiang and Wang, Yuqing and Shang, Ying and Zhang, Lijiao and Liu, Huan and Li, Zemin and Xue, Lixiang and Chen, Yahong and Sun, Yongchang and Zhang, Xu and Jin, Rong and Chang, Chun},
  title = {LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T-cells},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.01752-2023}
}
Kostenlos starten →